Duke University

Immunolight, LLC

Encore Health LLC

Novartis Ag

Gooden, David

Spector, Neil, L.

Xia, Wenle

Toone, Eric, J.

Walder, Harold

Beyer, Wayne, F.

Soderblom, Erik, J.

David M Gooden

Eric John Toone

George Edward Minno

William Garner

Margaret Garner

Frederic Avery Bourke, Jr

Tuan Vo-Dinh

Scott W Cousins

Priyatham S Mettu

Harold Walder

Ronald D Blum

Marc G Caron

Wayne F Beyer

Neil Lee Spector

Wayne F Beyer, Jr

Raul R Gainetdinov

Wenle Xia

Dewey G McCafferty

Julie A Pollock

Tatyana D Sotnikova

Erik J Soderblom

Frederic A Bourke

Willliam Garner

The presently disclosed subject matter is directed to compositions and methods for treating CaMKK2-mediated ophthalmic diseases, including but not limited to 1) ocular surface inflammatory diseases (OSIDs), including but not limited to ocular graft versus host disease, ocular cicatricial pemphigoid, vernal keratoconjunctivitis, allergic eye disease, meibomian gland dysfunction, aqueous tear deficiency (common dry eye disease), corneal scarring, and conjunctival scarring and fibrosis; 2) uveitis and other inflammatory diseases of the eye, including but not limited to keratitis, scleritis, iritis, iridocyclitis, intermediate uveitis, pars planitis, posterior uveitis, choroiditis, chorioretinitis, retinitis, or panuveitis of noninfectious, infectious, or idiopathic etiologies; and 3) 'back of the eye' retinal diseases, which include dry age-related macular degeneration, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular diseases (e.g. retinal vein occlusion, retinal artery occlusion), and retinal degenerations and dystrophies, in a subject. Particularly, the disclosed compounds exhibit improvements over STO-609, a well characterized specific inhibitor of CaMKK2. The disclosed compounds exhibit enhanced aqueous solubility and formulation, as well as elimination of non-binding isomers during production. The disclosed inhibitor compounds can be used to effectively treat ophthalmic diseases, cancers, appetite disorders, systemic inflammatory diseases, and the like.

Methods and compositions for drugs to treat ophthalmic diseases

Psoralen compounds of compounds having formulae 1A-10A, 1B-10B, 1C-10C, 1D-10D, 1E-10E, 1F-10F, 1G-10G, and 1H-5H as shown in FIG., and pharmaceutically acceptable salts thereof;

Methods and systems for treating cell proliferation disorders with psoralen derivatives

The present disclosure provides compositions and methods for treating ocular disorders in mammals especially in and not limited to humans and mice. The present disclosure further provides methods of treating cancer and appetite suppression using the compositions which are novel small molecule inhibitors of CaMKK2. In addition, these derived compositions can regulate non-ocular disorders, such as cancer and appetite suppression by modulating and inhibiting CaMKK2 and the regulation of the macrophage mediated diseases.

Composition and methods for the treatment of CaMKK2-mediated disorders

Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract.

Method of treating presbyopia using dithiol compounds and their derivatives

The present invention is directed to a method of treating Parkinson's disease using arylcyclopropylamine compounds. The arylcyclopropylamine compounds have the following formula wherein R, R, R, R, Rand Rare described herein.

Methods of treatment using arylcyclopropylamine compounds

Dithiol compounds, derivatives, and uses therefor

Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.

Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders

Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage.

Choline esters

Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating an ocular disease, especially presbyopia and cataract. Also provided are methods of treating an ocular disease, the methods comprising administering to a subject an active agent and an adjunctive agent.

Methods of treating ocular diseases using derivatives of lipoic acid

Methods of treating ocular diseases using dithiol compounds, their derivatives, and pharmaceutically acceptable salts thereof are disclosed. In particular, methods using dithiol compounds that comprise derivatives of lipoic acid are described. The dithiol compounds are especially useful for treating ocular diseases such as presbyopia and cataract.

Growing community of inventors

Durham, NC, United States of America

David M Gooden